Exercise-based cardiac rehabilitation for adults after heart valve surgery

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Background: The impact of exercise-based cardiac rehabilitation (CR) following heart valve surgery is uncertain. We conducted an update of this systematic review and a meta-analysis to assess randomised controlled trial evidence for the use of exercise-based CR following heart valve surgery. Objectives: To assess the benefits and harms of exercise-based CR compared with no exercise training in adults following heart valve surgery or repair, including both percutaneous and surgical procedures. We considered CR programmes consisting of exercise training with or without another intervention (such as an intervention with a psycho-educational component). Search methods: We searched the Cochrane Central Register of Clinical Trials (CENTRAL), in the Cochrane Library; MEDLINE (Ovid); Embase (Ovid); the Cumulative Index to Nursing and Allied Health Literature (CINAHL; EBSCO); PsycINFO (Ovid); Latin American Caribbean Health Sciences Literature (LILACS; Bireme); and Conference Proceedings Citation Index-Science (CPCI-S) on the Web of Science (Clarivate Analytics) on 10 January 2020. We searched for ongoing trials from ClinicalTrials.gov, Clinical-trials.com, and the World Health Organization International Clinical Trials Registry Platform on 15 May 2020. Selection criteria: We included randomised controlled trials that compared exercise-based CR interventions with no exercise training. Trial participants comprised adults aged 18 years or older who had undergone heart valve surgery for heart valve disease (from any cause) and had received heart valve replacement or heart valve repair. Both percutaneous and surgical procedures were included. Data collection and analysis: Two review authors independently extracted data. We assessed the risk of systematic errors (‘bias’) by evaluating risk domains using the 'Risk of bias' (RoB2) tool. We assessed clinical and statistical heterogeneity. We performed meta-analyses using both fixed-effect and random-effects models. We used the GRADE approach to assess the quality of evidence for primary outcomes (all-cause mortality, all-cause hospitalisation, and health-related quality of life). Main results: We included six trials with a total of 364 participants who have had open or percutaneous heart valve surgery. For this updated review, we identified four additional trials (216 participants). One trial had an overall low risk of bias, and we classified the remaining five trials as having some concerns. Follow-up ranged across included trials from 3 to 24 months. Based on data at longest follow-up, a total of nine participants died: 4 CR versus 5 control (relative risk (RR) 0.83, 95% confidence interval (CI) 0.26 to 2.68; 2 trials, 131 participants; GRADE quality of evidence very low). No trials reported on cardiovascular mortality. One trial reported one cardiac-related hospitalisation in the CR group and none in the control group (RR 2.72, 95% CI 0.11 to 65.56; 1 trial, 122 participants; GRADE quality of evidence very low). We are uncertain about health-related quality of life at completion of the intervention in CR compared to control (Short Form (SF)-12/36 mental component: mean difference (MD) 1.28, 95% CI -1.60 to 4.16; 2 trials, 150 participants; GRADE quality of evidence very low; and SF-12/36 physical component: MD 2.99, 95% CI -5.24 to 11.21; 2 trials, 150 participants; GRADE quality of evidence very low), or at longest follow-up (SF-12/36 mental component: MD -1.45, 95% CI -4.70 to 1.80; 2 trials, 139 participants; GRADE quality of evidence very low; and SF-12/36 physical component: MD -0.87, 95% CI -3.57 to 1.83; 2 trials, 139 participants; GRADE quality of evidence very low). Authors' conclusions: Due to lack of evidence and the very low quality of available evidence, this updated review is uncertain about the impact of exercise-CR in this population in terms of mortality, hospitalisation, and health-related quality of life. High-quality (low risk of bias) evidence on the impact of CR is needed to inform clinical guidelines and routine practice.

OriginalsprogEngelsk
ArtikelnummerCD010876
TidsskriftCochrane Database of Systematic Reviews
Vol/bind2021
Udgave nummer5
ISSN1465-1858
DOI
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
We thank all the authors who provided important contributions to drafting of this review. We are indebted to Swenyu Hu, Danish Institute for Trial Abroad, Copenhagen, Denmark, and Henry Lishi Li, London School of Hygiene and Tropical Medicine, London, UK, for their excellent translation services. Further, we thank Dr. Lindsey Anderson for alignment of this review with the other Cochrane Reviews in the cardiac rehabilitation portfolio. We thank Christian Gluud, Lars Kober, and Christian Hassager, who were also co-authors of the previous version of this review; Michele Hilton Boon, who provided an independent RoB2 assessment for primary outcomes of the Sibilitz 2016 trial; and Dr.?Wilby Williamson from the University of Oxford, who peer-reviewed the manuscript. The Background and Methods sections of this review are based on a standard template provided by the Cochrane Heart Group.

Funding Information:
Ann-Dorthe Zwisler declares financial support for expert testimony as part of her employment as professor.

Funding Information:
Study was supported by the Medical Research Council of Southeast Sweden (FORSS) and ALF Grants, Region Östergötland

Funding Information:
The RECOVER-TAVI trial was funded through a pump priming grant from the Royal Brompton & Hare-field NHS Foundation Trust Biomedical Research Unit Conflicts of Interest: MD has received research grants, consultancy and proctorship fees from Astra Zeneca, Eli Lilly, Abbott Vascular, Daiichi Sankyo, Daiichi Sankyo, Lilly Alliance, Abbott Vascular, Sanofi, Medtronic, Boston Scientific, Edwards Lifesciences. NM has received honoraria, consultancy and proctorship fees from Abbott Vascular, Medtronic, and Edwards Lifesciences. MS has received research grants, consultancy and proctorship fees from Medtronic, Edwards Lifesciences, St Jude (now Abbott Vascular), and Boston Scientific. RST is the lead for the ongoing portfolio of Cochrane Reviews of cardiac rehabilitation. RST is a named scientific advisor for ongoing National Institutes of Health and Care Excellence (NICE) updated clinical guidelines for management of heart failure (CG108). HP is a member of the British Association for Cardiovascular Prevention and Rehabilitation (BACPR) and the Association of Chartered Physiotherapists in Cardiac Rehabilitation (ACPICR). HP chaired the referenced ACPICR Working Group for the national standards document Thirteen control group patients completed the study assessment. Ten in the 13 intervention group completed the CR and assessment; 3 were too unwell to do so; and all patients were followed up

Funding Information:
This study received grant support from the German Heart Foundation/German Foundation of Heart Research (Frankfurt, Germany; F/14/12). Author BL received financial support from the German Cardiac Society (Düsseldorf, Germany) via the Otto-Hess-Research-Grant

Publisher Copyright:
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ID: 303579014